JAK3 and breast cancer: To examine the efficacy of the NICE program, we screened a library of 79 protein kinase inhibitors and validated the effect of CaMKII, JAK-3 and IκB IKK inhibitors on mammosphere formation and EMT of breast cancer cells, which suggest potential target for treatment of breast cancer via modulating the development and growth of CSC.